This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

News
31 Aug 2011

Valeant to Acquire Afexa for $76M

Valeant Pharmaceuticals will acquire cold and flu medicine maker Afexa Life Sciences for approximately $76 million.

Canadian drugmaker Valeant Pharmaceuticals International has inked a deal to acquire cold and flu medicine maker Afexa Life Sciences for approximately $76 million.

 

Afexa, a health-science company headquartered in Alberta, Canada, markets several consumer brands, such as COLD-FX and COLDSORE-FX, and has annual revenues of approximately $40 million.

 

Full details of the offer will be included in a take-over bid circular, which is expected to be mailed to share holders by September 9, 2011. 

 

J. Michael Pearson, chairman and chief executive officer, said,"Afexa's strong franchise of consumer brands will be a solid addition to our developing OTC product portfolio in Canada. Afexa's product lin

Related News